projet NLP Matthias Rey, Clément Labbé


# commandes : 
python train_classifier.py
python QA/train_on_squad.py
streamlit run app.py



========================================================================================================

BREAKING: Scientists Discover Government Has Been Hiding Cure for Cancer for 30 Years!

You won't believe what mainstream media isn't telling you! A whistleblower from inside the pharmaceutical industry has revealed shocking documents proving that a complete cure for all types of cancer has existed since 1995. The treatment, which costs less than $50 to produce, has been deliberately suppressed by Big Pharma to protect their trillion-dollar chemotherapy profits.

Dr. Robert Henderson, a former researcher at BioTech Solutions, released 500 pages of confidential documents showing successful trials on over 10,000 patients. The cure involves a simple combination of natural herbs that pharmaceutical companies don't want you to know about because they can't patent it.

"They threatened my family when I tried to publish these findings," Henderson told reporters in an exclusive interview. "The FDA is completely controlled by drug company executives who profit from keeping people sick. Wake up America!"

The documents show that cancer mortality rates could be reduced to nearly zero within months if this treatment were made available. Multiple independent doctors have confirmed the authenticity of these documents, but their names are being withheld for their safety.

This bombshell revelation comes as cancer rates continue to skyrocket across the nation. Industry insiders estimate that pharmaceutical companies make over $200 billion annually from cancer treatments that they know don't work as well as this suppressed cure.

Share this article before it gets taken down! The truth is finally coming out, and they can't silence us all.

======================================================================================================================================
New Cancer Treatment Shows Promise in Early Clinical Trials

Researchers at Johns Hopkins University have reported encouraging results from a Phase II clinical trial of an experimental immunotherapy treatment for advanced melanoma. The study, published today in the Journal of Clinical Oncology, involved 127 patients who had not responded to standard treatments.

The treatment, known as pembrolizumab, works by blocking a protein called PD-1 that prevents the immune system from attacking cancer cells. In the trial, approximately 38 percent of patients showed significant tumor reduction after six months of treatment.

Dr. Sarah Mitchell, lead researcher on the study, cautioned that these are preliminary results. "While we're encouraged by what we've seen, this is still early-stage research," Mitchell said. "We need larger trials and longer follow-up periods to fully understand the treatment's effectiveness and potential side effects."

The most common side effects observed were fatigue, skin rash, and in some cases, inflammation of healthy tissues. Three patients discontinued treatment due to severe immune-related complications.

The pharmaceutical company Merck, which developed pembrolizumab, has begun enrolling patients for a Phase III trial that will compare the new treatment against current standard therapies. Results from that larger study are expected in 2027.

The National Cancer Institute notes that immunotherapy represents one of several promising approaches in cancer treatment, alongside traditional chemotherapy, radiation, and targeted therapies. Most cancer types require combination treatments tailored to individual patients.

"This is an important step forward, but patients should discuss all available treatment options with their oncologists," said Dr. James Chen, director of the American Cancer Society's research division. "Every cancer case is unique."

The study was funded by the National Institutes of Health and Merck & Co.

=======================================================================================================

what is this article about ?

when will it end ?

how many patients are there?


==================================================


